Ipsen adds a chain to its early development pipeline by partnering with Simcere

Announcement

Ipsen, a French-based biopharmaceutical company concentrating on marketing and drug development in neuroscience, rare disease and oncology spaces, has proudly revealed its exclusive licensing agreement for its SIM0613, an antibody-drug conjugate (ADC), to gain universal rights in Greater China with its excellent potential to thrive in the market.

On concentrating on the LRRC15 protein, the SIM0613 is engineered to improve tumor penetration and classify anti-tumor activity in solid tumors that are seeking effective treatment. The expansion to the early development pipeline with Simcere Zaiming’s creative antibody drug conjugate will ease the stream of drug development.

Ipsen's decision to expand its early development pipeline with Simcere’s excellence stands as an opportunity for Ipsen to enter Greater China and prove its potential. The exposure of Ipsen’s comprehensive pipeline will attract new projects, development and partnerships ahead. This will not only profit Ipsen, but it will also give Simcere a chance to learn the potential value of Ipsen’s initiatives so far.

Agreement specification

According to the terms and conditions of the agreement, Simcere Zaiming is qualified to receive around $1.06B, incorporating development, commercial, regulatory and upfront milestone payments, including the fixed royalties on sales success and regulatory and development approvals. The agreement states that Ipsen will get manufacturing rights, as per the tech transfer process.

Further, it will frame the responsibility accordingly for all operations outside Greater China. This involves submission of the applications of Investigational New Drug and Clinical Trial, and the updates and status of Phase 1 preparation operations.

The Head of Research and Development, PhD EVP, Ipsen, Christelle Huguet, said, “This latest announcement emphasises our unique vision to run innovation and frame the next generation of oncology. By modernising the remarkable, promising therapies early, we double the capacity to improve patient outcomes worldwide. The SIM0613 ADC exemplifies our ambition towards the groundbreaking science that opens doors for new possibilities for the needy population. This ambition is built on the company’s emerging research and early development portfolio, with almost 20 programs performing excellently since 2020.”

The PhD, CEO of Simcere Zaiming, Renhong Tang, said, “SIM0613 is established through Simcere Zaiming’s exclusive antibody-drug conjugate platform. We are thrilled to join hands with Ipsen on this promising novel drug participant. We’re looking forward to executing our joint work in advancing the clinical development of SIM0613.”